Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| 89R13815 TYPED | ||
| By: Parker | S.B. No. 1357 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to a cancer clinical trial participation program. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. The legislature finds that: | |
| (1) the ability to translate medical findings from | |
| research to practice relies largely on robust subject participation | |
| and a diverse subject participation pool in clinical trials; | |
| (2) diverse subject participation in cancer clinical | |
| trials depends significantly on whether an individual is able to | |
| afford ancillary costs, including transportation and lodging, | |
| during the course of participation in a cancer clinical trial; | |
| (3) a national study conducted in 2015 found that | |
| individuals from households with an annual income of less than | |
| $50,000 were 30 percent less likely to participate in cancer | |
| clinical trials; | |
| (4) direct and indirect costs, including | |
| transportation, lodging, and child-care expenses, prevent eligible | |
| individuals from participating in cancer clinical trials according | |
| to the National Cancer Institute; | |
| (5) the disparities in subject participation in cancer | |
| clinical trials threaten the basic ethical underpinning of clinical | |
| research, which requires the benefits of the research to be made | |
| available equitably among all eligible individuals; | |
| (6) while the United States Food and Drug | |
| Administration recently confirmed to Congress and provided | |
| guidance on its Internet website that reimbursement of direct | |
| subject-incurred expenses is not an inducement, many | |
| organizations, research sponsors, philanthropic individuals, | |
| charitable organizations, governmental entities, and other persons | |
| still operate under the misconception that such reimbursement is an | |
| inducement; | |
| (7) it is the intent of the legislature to enact | |
| legislation to further define and establish a clear difference | |
| between items considered to be an inducement for a subject to | |
| participate in a cancer clinical trial and the reimbursement of | |
| expenses for participating in a cancer clinical trial; and | |
| (8) further clarification of the United States Food | |
| and Drug Administration's confirmation and guidance is appropriate | |
| and important to improve subject participation in cancer clinical | |
| trials, which is the primary intent of this legislation. | |
| SECTION 2. Subtitle B, Title 2, Health and Safety Code, is | |
| amended by adding Chapter 50 to read as follows: | |
| CHAPTER 50. CANCER CLINICAL TRIAL PARTICIPATION PROGRAM | |
| Sec. 50.0001. DEFINITIONS. In this chapter: | |
| (1) "Cancer clinical trial" means a research study | |
| that subjects an individual to a new cancer treatment, including a | |
| medication, chemotherapy, adult stem cell therapy, or other | |
| treatment. | |
| (2) "Inducement" means the payment of money, including | |
| a lump-sum or salary payment, to an individual for the individual's | |
| participation in a cancer clinical trial. | |
| (3) "Program" means the cancer clinical trial | |
| participation program established under this chapter. | |
| (4) "Subject" means an individual who participates in | |
| the program. | |
| Sec. 50.0002. ESTABLISHMENT. A public or private | |
| institution of higher education, as defined by Section 61.003, | |
| Education Code, an independent research organization located in | |
| Texas, or |
|
| and implement the cancer clinical trial participation program to | |
| provide reimbursement to subjects for ancillary costs associated | |
| with participation in a cancer clinical trial, including costs for: | |
| (1) travel; | |
| (2) lodging; | |
| (3) parking and tolls; | |
| (4) meals or groceries; | |
| (5) childcare; and | |
| |
|
| organization. | |
| Sec. 50.0003. REQUIREMENTS; NOTICE. (a) The program: | |
| (1) must collaborate with physicians and health care | |
| providers to notify a prospective subject about the program when: | |
| (A) the prospective subject provides informed | |
| consent for a cancer clinical trial; or | |
| (B) funding is available to provide the program | |
| for the cancer clinical trial in which the prospective subject | |
| participates; | |
| (2) must reimburse subjects based on financial need, | |
| which may include reimbursement to subjects whose income is at or | |
| below 700 percent of the federal poverty level; | |
| (3) must provide reimbursement for ancillary costs, | |
| including costs described by Section 50.0002, to eliminate the | |
| financial barriers to enrollment in a clinical trial; | |
| (4) may provide reimbursement for reasonable | |
| ancillary costs, including costs described by Section 50.0002, to | |
| one family member, friend, or other person who attends a cancer | |
| clinical trial to support a subject; and | |
| (5) must comply with applicable federal and state | |
| laws. | |
| (b) The public or private institution of higher education, | |
| as defined by Section 61.003, Education Code, the independent | |
| research organization located in Texas, or the independent, | |
| third-party organization administering the program shall provide | |
| written notice to prospective subjects of the requirements | |
| described by Subsection (a). | |
| Sec. 50.0004. REIMBURSEMENT REQUIREMENTS; NOTICE. (a) A | |
| reimbursement under the program must: | |
| (1) be reviewed and approved by the institutional | |
| review board associated with the cancer clinical trial for which | |
| the reimbursement is provided; and | |
| (2) comply with applicable federal and state laws. | |
| (b) The independent, third-party organization operating the | |
| program is not required to obtain approval from an institutional | |
| review board on the financial eligibility of a subject who is | |
| medically eligible for the program. | |
| (c) The public or private institution of higher education, | |
| as defined by Section 61.003, Education Code, the independent | |
| research organization located in Texas, or the independent, | |
| third-party organization operating the program shall provide | |
| written notice to a subject on: | |
| (1) the nature and availability of the ancillary | |
| financial support under the program; and | |
| (2) the program's general guidelines on financial | |
| eligibility. | |
| Sec. 50.0005. REIMBURSEMENT STATUS AS INDUCEMENT. | |
| Reimbursement to a subject of ancillary costs under the program: | |
| (1) does not constitute an inducement to participate | |
| in a cancer clinical trial; | |
| (2) is not considered coercion or the exertion of | |
| undue influence to participate in a cancer clinical trial; and | |
| (3) is meant to accomplish parity in access to cancer | |
| clinical trials and remove barriers to participation in cancer | |
| clinical trials for financially burdened subjects. | |
| Sec. 50.0006. FUNDING. The public or private institution | |
| of higher education, as defined by Section 61.003, Education Code, | |
| the independent research organization located in Texas, or the | |
| independent, third-party organization that administers the program | |
| may accept gifts, grants, and donations from any public or private | |
| source to implement this chapter. | |
| Sec. 50.0007. COLLABORATION. The public or private | |
| institution of higher education, as defined by Section 61.003, | |
| Education Code, the independent research organization located in | |
| Texas, or the independent, third-party organization that | |
| administers the program may collaborate with the Cancer Prevention | |
| and Research Institute of Texas established under Chapter 102 to | |
| provide reimbursement under the program. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.